Syros Pharmaceuticals (NASDAQ:SYRS) Earns Sell Rating from Analysts at StockNews.com

Equities researchers at StockNews.com began coverage on shares of Syros Pharmaceuticals (NASDAQ:SYRS) in a research note issued to investors on Friday. The brokerage set a “sell” rating on the stock.

Syros Pharmaceuticals Price Performance

NASDAQ:SYRS opened at $0.06 on Friday. The stock has a market cap of $1.65 million, a P/E ratio of -0.02 and a beta of 1.31. The company has a fifty day moving average price of $0.16 and a 200 day moving average price of $0.85. Syros Pharmaceuticals has a one year low of $0.06 and a one year high of $6.93.

Institutional Investors Weigh In On Syros Pharmaceuticals

A number of institutional investors have recently added to or reduced their stakes in SYRS. Two Sigma Securities LLC bought a new stake in shares of Syros Pharmaceuticals in the 4th quarter worth approximately $25,000. Exome Asset Management LLC raised its stake in shares of Syros Pharmaceuticals by 87.6% in the third quarter. Exome Asset Management LLC now owns 298,575 shares of the company’s stock valued at $642,000 after purchasing an additional 139,400 shares in the last quarter. Finally, GSA Capital Partners LLP bought a new position in Syros Pharmaceuticals in the third quarter worth $34,000. 91.47% of the stock is owned by institutional investors and hedge funds.

Syros Pharmaceuticals Company Profile

Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors.